Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
spironolactone + dapagliflozin
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of spironolactone, a mineralocorticoid receptor antagonist, and dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This combination has shown effectiveness in treating heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF). Spironolactone acts by blocking aldosterone receptors in the distal tubules, causing increased sodium and water excretion while retaining potassium. Dapagliflozin works by inhibiting SGLT2 in the proximal tubule of the nephron, allowing glucose to be excreted in urine and reducing cardiac workload.
- Other names
- Dapagliflozin and Spironolactone combinationDapagliflozin plus Spironolactone
02
Targets
MR (Mineralocorticoid receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on spironolactone + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on spironolactone + dapagliflozin.